CBD resistant Salmonella strains are susceptible to epsilon 34 phage tailspike protein. 2023

Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
The Microbiology Program, College of Science, Technology, Engineering, and Mathematics (C-STEM), Alabama State University, Montgomery, AL, United States.

The rise of antimicrobial resistance is a global public health crisis that threatens the effective control and prevention of infections. Due to the emergence of pandrug-resistant bacteria, most antibiotics have lost their efficacy. Bacteriophages or their components are known to target bacterial cell walls, cell membranes, and lipopolysaccharides (LPS) and hydrolyze them. Bacteriophages being the natural predators of pathogenic bacteria, are inevitably categorized as "human friends", thus fulfilling the adage that "the enemy of my enemy is my friend". Leveraging on their lethal capabilities against pathogenic bacteria, researchers are searching for more ways to overcome the current antibiotic resistance challenge. In this study, we expressed and purified epsilon 34 phage tailspike protein (E34 TSP) from the E34 TSP gene, then assessed the ability of this bacteriophage protein in the killing of two CBD-resistant strains of Salmonella spp. We also assessed the ability of the tailspike protein to cause bacteria membrane disruption, and dehydrogenase depletion. We observed that the combined treatment of CBD-resistant strains of Salmonella with CBD and E34 TSP showed poor killing ability whereas the monotreatment with E34 TSP showed considerably higher killing efficiency. This study demonstrates that the inhibition of the bacteria by E34 TSP was due in part to membrane disruption, and dehydrogenase inactivation by the protein. The results of this work provides an interesting background to highlight the crucial role phage protein such as E34 TSP could play in pathogenic bacterial control.

UI MeSH Term Description Entries

Related Publications

Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
January 2007, Gene,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
January 1995, Journal of structural biology,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
December 1964, Japanese journal of microbiology,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
November 1975, Virology,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
July 1978, The Journal of antimicrobial chemotherapy,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
January 2003, The Journal of biological chemistry,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
October 1996, Proceedings of the National Academy of Sciences of the United States of America,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
November 1994, Current biology : CB,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
October 2010, Biochemical Society transactions,
Iddrisu Ibrahim, and Joseph Atia Ayariga, and Junhuan Xu, and Ayomide Adebanjo, and Boakai K Robertson, and Michelle Samuel-Foo, and Olufemi S Ajayi
June 2020, Applied and environmental microbiology,
Copied contents to your clipboard!